Gilead Sciences Inc. scored an exclusive deal with CVS Health Corp., as its two hepatitis C medicines, Harvoni and Sovaldi, will be available only for CVS customers.
Sovaldi costs $84,000 for a 12-week course of treatment, and Harvoni costs $94,500 for 12 weeks. The drugs will be available in health exchange marketplaces, Medicare Part D, and Medicaid formularies.
Viekira Pak – AbbVie Inc.’s rival combo drug to Harvoni and Sovaldi – will be excluded from CVS’s drug formulary of approved medications, except in cases when it is medically necessary. Viekira Pak received Food and Drug Administration approval in December of 2014.
For more information, go to www.bloomberg.com.